Mayo Clinic (Rochester)

Accepting patients

CFT7455

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more
  • Phase 1/2

Accepting patients

CAMMA-2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1/2

Not yet accepting

KarMMa-9

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Learn more
  • CAR T Cell
  • Immunomodulatory Drug
  • BCMA
  • Randomization
  • Phase 3

Not yet accepting

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Not yet accepting

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Not currently accepting

CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2
  • Has results

Accepting patients

ORIC-533

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Learn more
  • CD73 Inhibitor
  • Phase 1
  • Has results

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

REACH

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Learn more
  • Proteasome Inhibitor
  • Phase 2

Accepting patients

VSV-hIFNbeta-NIS

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Learn more
  • Phase 1
7 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase